Valeant Pharmaceuticals (VRX) menja ime kompanije u Bausch Health (BHC)

Kompanija Valeant Pharmaceuticals International, Inc. (NYSE: VRX) je objavila da će promeniti ime na Bausch Health Companies Inc., zaključno sa Julom 2018. godine.
“Kreiranje Bausch zdravstvenih kompanija je veliki korak napred u našoj transformaciji”, rekao je Joseph C. Papa, predsednik i izvršni direktor Valeanta. “Ime Bauš odlikuje bogata istorija inovacije, izdržljivosti i posvećenosti zdravlju pacijenta od kada je JJ Bausch otvorio svoju prvu prodavnicu optičkih proizvoda pre više od 165 godina.Ovi kvaliteti čine osnovu danas, dok mi nastavljamo s izgradnjom inovativne kompanije koja teži poboljšanju zdravlja pacijenata širom sveta. ”

Od pridruživanja Valeant-u u maju 2016. godine, g. Papa i njegov vodeći tim počeli su višegodišnje napore da preokrenu kompaniju. U protekle dve godine, Kompanija je završila više od desetak prodaja za strateško usmeravanje poslovanja, smanjila dug za više od 20% i rešila je brojna regulatorna pitanja.

“Sada je pravo vreme u našem preokretu da udružimo ključna preduzeća naše kompanije, podružnice i brendove pod imenom Bausch Health”, nastavio je gospodin Papa. “Smatramo da Bausch Health Companies sve više predstavlja celovit opseg Kompanije danas – lider u razvoju i proizvodnji širokog spektra farmaceutskih, medicinskih uređaja i proizvoda bez prekida, prvenstveno u terapijskim oblastima očnog zdravlja, gastroenterologije i dermatologije. ”

S obzirom na to da preduzeća i podružnice kompanije imaju snažan kapital brenda, svi subjekti koji imaju odvojene uspostavljene brendove nastaviće da rade pod korporativnim kišobranom koristeći njihova postojeća imena.

U sklopu promene imena, Kompanija će u julu 2018. godine predstaviti novi identitet korporativnog brenda, u koji će biti uključene nove slike i veb stranica, te će se trgovati pod novim simbolom BHC. Do tada će kompanija nastaviti da trguje na Njujorškoj berzi i berzi Toronto pod njenim sadašnjim simbolom VRX.

“Završili smo veliku procenu entitetskih imena dostupnih u našem portfoliu i procijenili nekoliko potencijalnih novih imena. Kako je naš pregled napredovao, postalo je jasno da Bausch Health Companies najbolje predstavlja kompaniju kojoj smo danas”, rekao je gospodin Papa. “Sa istorijom koja se kreće od stvaranja revolucionarnih okvira Vulcanita za oči i oko očiju 1861. godine, da je prva koja masovno proizvodi i prodaje mekana kontaktna sočiva na globalnom nivou 1971. godine, brend Bauš je sinonim za inovacije i kvalitet”.
Obaveštenje o promeni imena je dostavljeno i Njujorškoj berzi i Torontskoj berzi, a efektivnost promene imena podleže regulativi ovih berzi.

ORIGANALNI TEXT >
https://www.streetinsider.com/Corporate+News/Valeant+Pharma+%28VRX%29+Confirms+Name+Change+to+Bausch+Health+%28BHC%29/14158334.html

Valeant Pharma (VRX) Confirms Name Change to Bausch Health (BHC)

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that the Company will change its name to Bausch Health Companies Inc., effective in July 2018.
“Becoming Bausch Health Companies is a major step forward in our transformation,” said Joseph C. Papa, chairman and CEO, Valeant. “The Bausch name embodies the rich history of innovation, fortitude and dedication to patient health dating back to when J.J. Bausch opened his first optical goods shop more than 165 years ago. These qualities form the foundation of who we are today as we continue to build an innovative company striving to improve the health of patients globally.”

Since joining Valeant in May 2016, Mr. Papa and his leadership team have embarked on a multi-year effort to turnaround the Company. In the past two years, the Company has completed more than a dozen divestitures to strategically streamline operations, has reduced debt by more than 20%, and has resolved numerous legacy issues.

“Now is the right time in our turnaround to unite our Company’s core businesses, subsidiaries and brands under the Bausch Health name,” continued Mr. Papa. “We believe Bausch Health Companies more accurately represents the full scope of the Company today – a leader in the development and manufacture of a wide range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology.”
Because the Company’s businesses and subsidiaries have strong brand equity, all entities that have separate established brands will continue to operate under the corporate umbrella using their existing names.

As part of the name change, the Company will roll out a new corporate brand identity in July 2018, which will include new imagery and web site, and will trade under a new symbol, BHC. Until that time, the Company will continue to trade on the New York Stock Exchange and Toronto Stock Exchange under its present symbol, VRX.

“We completed an extensive assessment of the name entities available from within our portfolio and also assessed several potential new names. As our review progressed, it became clear that Bausch Health Companies best represents the company we are today,” said Mr. Papa. “With a history that ranges from creating revolutionary Vulcanite eye glass frames in 1861 to being the first to mass produce and market soft contact lenses globally in 1971, the Bausch brand is synonymous with innovation and quality.”

Notice of the name change has been submitted to both the New York Stock Exchange and the Toronto Stock Exchange, and the effectiveness of the name change is subject to the satisfaction of customary conditions of such exchanges.